β-U10

Β-U10
Identifiers
	IUPAC name N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylnaphthalene-2-carboxamide;
CAS Number	67579-80-0;
PubChem CID	54524276;
ChemSpider	109107961;
Chemical and physical data
Formula	C20H26N2O
Molar mass	310.441 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)[C@@H]1CCCC[C@H]1N(C)C(=O)C2=CC3=CC=CC=C3C=C2;
	InChI InChI=1S/C20H26N2O/c1-21(2)18-10-6-7-11-19(18)22(3)20(23)17-13-12-15-8-4-5-9-16(15)14-17/h4-5,8-9,12-14,18-19H,6-7,10-11H2,1-3H3/t18-,19-/m1/s1; Key:YRZZSLYUFWBIIK-RTBURBONSA-N;

β‐U10 is an opioid analgesic which has been sold as a designer drug, closely related to the so-called utopioid derivative U-47700. It is slightly less than half the potency of U-47700 in animal testing, but this still makes it several times the potency of morphine. It has generally been identified by analytical laboratories after having been misrepresented as better known drugs such as heroin, usually as a mixture with other designer opioids and/or sedatives, rather than intentionally purchased in its own right.^[1]^[2]^[3]

References

^ West H, Fitzgerald JL, Hopkins KL, Leeming MG, DiRago M, Gerostamoulos D, et al. (September 2022). "Trace residue identification, characterization, and longitudinal monitoring of the novel synthetic opioid β-U10, from discarded drug paraphernalia". Drug Testing and Analysis. 14 (9): 1576–1586. doi:10.1002/dta.3284. PMC 9542064. PMID 35562123.
^ Vandeputte MM, Stove CP (March 2024). "In vitro μ-opioid receptor activation potential of U10 and β-U10, positional isomers of the synthetic opioid naphthyl U-47700". Drug Testing and Analysis. 16 (3): 323–326. doi:10.1002/dta.3554. hdl:1854/LU-01J2DRXRXFJ7TM6R0P7MW06T6Y. PMID 37482925.
^ Mammoliti E, Nielsen S, Roxburgh A (January 2026). "A Scoping Review of the Emergence of Novel Synthetic Opioids in Australian Drug Markets: What Does This Mean for Harm Reduction Responses?". Drug and Alcohol Review. 45 (1) e14079. doi:10.1111/dar.14079. PMC 12682423. PMID 40434927.

[1] West H, Fitzgerald JL, Hopkins KL, Leeming MG, DiRago M, Gerostamoulos D, et al. (September 2022). "Trace residue identification, characterization, and longitudinal monitoring of the novel synthetic opioid β-U10, from discarded drug paraphernalia". Drug Testing and Analysis. 14 (9): 1576–1586. doi:10.1002/dta.3284. PMC 9542064. PMID 35562123.

[2] Vandeputte MM, Stove CP (March 2024). "In vitro μ-opioid receptor activation potential of U10 and β-U10, positional isomers of the synthetic opioid naphthyl U-47700". Drug Testing and Analysis. 16 (3): 323–326. doi:10.1002/dta.3554. hdl:1854/LU-01J2DRXRXFJ7TM6R0P7MW06T6Y. PMID 37482925.

[3] Mammoliti E, Nielsen S, Roxburgh A (January 2026). "A Scoping Review of the Emergence of Novel Synthetic Opioids in Australian Drug Markets: What Does This Mean for Harm Reduction Responses?". Drug and Alcohol Review. 45 (1) e14079. doi:10.1111/dar.14079. PMC 12682423. PMID 40434927.

[1]

[2]

[3]

See also

References